UBI Pharma Past Earnings Performance
Past criteria checks 2/6
UBI Pharma has been growing earnings at an average annual rate of 66.9%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 10.3% per year. UBI Pharma's return on equity is 0.07%, and it has net margins of 0.1%.
Key information
66.9%
Earnings growth rate
67.0%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 10.3% |
| Return on equity | 0.07% |
| Net Margin | 0.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How UBI Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 649 | 1 | 93 | 99 |
| 30 Sep 23 | 650 | 21 | 92 | 115 |
| 30 Jun 23 | 651 | 42 | 90 | 131 |
| 31 Mar 23 | 642 | 44 | 91 | 141 |
| 31 Dec 22 | 634 | 47 | 92 | 152 |
| 30 Sep 22 | 660 | 64 | 92 | 140 |
| 30 Jun 22 | 686 | 81 | 91 | 128 |
| 31 Mar 22 | 665 | 52 | 88 | 137 |
| 31 Dec 21 | 644 | 22 | 85 | 145 |
| 30 Sep 21 | 577 | -1 | 107 | 149 |
| 30 Jun 21 | 510 | -24 | 129 | 153 |
| 31 Mar 21 | 484 | -49 | 140 | 145 |
| 31 Dec 20 | 458 | -74 | 152 | 136 |
| 30 Sep 20 | 467 | -149 | 137 | 167 |
| 30 Jun 20 | 476 | -223 | 122 | 197 |
| 31 Mar 20 | 478 | -233 | 127 | 205 |
| 31 Dec 19 | 480 | -242 | 133 | 213 |
| 30 Sep 19 | 459 | -242 | 129 | 220 |
| 30 Jun 19 | 438 | -242 | 124 | 228 |
| 31 Mar 19 | 431 | -241 | 107 | 239 |
| 31 Dec 18 | 424 | -241 | 90 | 250 |
| 30 Sep 18 | 412 | -213 | 81 | 220 |
| 30 Jun 18 | 400 | -185 | 73 | 191 |
| 31 Mar 18 | 366 | -176 | 66 | 179 |
| 31 Dec 17 | 333 | -167 | 59 | 168 |
| 30 Sep 17 | 335 | -204 | 55 | 206 |
| 30 Jun 17 | 337 | -241 | 51 | 244 |
| 31 Mar 17 | 347 | -233 | 52 | 243 |
| 31 Dec 16 | 358 | -226 | 53 | 241 |
| 30 Sep 16 | 389 | -135 | 54 | 187 |
| 30 Jun 16 | 421 | -43 | 55 | 134 |
| 31 Mar 16 | 417 | -21 | 54 | 106 |
| 31 Dec 15 | 413 | 2 | 54 | 78 |
| 31 Dec 14 | 409 | 39 | 42 | 29 |
Quality Earnings: 6562 has high quality earnings.
Growing Profit Margin: 6562's current net profit margins (0.1%) are lower than last year (7.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6562 has become profitable over the past 5 years, growing earnings by 66.9% per year.
Accelerating Growth: 6562's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 6562 had negative earnings growth (-98.3%) over the past year, making it difficult to compare to the Biotechs industry average (-8.8%).
Return on Equity
High ROE: 6562's Return on Equity (0.07%) is considered low.